Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Inhibits Experimental Autoimmune Thyroiditis by the Expansion of CD4+CD25+ Regulatory T Cells
Open Access
- 13 November 2008
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 150 (4), 2000-2007
- https://doi.org/10.1210/en.2008-1389
Abstract
There have been several reports that TNF-related apoptosis-inducing ligand (TRAIL) has the ability to suppress the development of experimental autoimmune diseases, including a mouse model of experimental autoimmune encephalomyelitis, a rabbit model of rheumatoid arthritis, type 1 diabetes mellitus, in mice and experimental autoimmune thyroiditis (EAT) in mice. However, the mechanism underlying TRAIL effect is not well defined. In the present study, we specifically examined TRAIL effects on CD4+CD25+ regulatory T cells. CD4+CD25+ T cells prepared from mouse thyroglobulin (mTg)-immunized CBA/J mice proliferate in the presence of TRAIL and dendritic cells in vitro. These CD4+CD25+ T cells included both CD4+CD25+CD45RBLow (regulatory) and CD4+CD25+CD45RBHigh (effector) T cells. Our results demonstrated that mTg-immunized mice treated with TRAIL showed significant increases in the number of CD4+CD25+CD45RBLow T cells compared with mice immunized with mTg alone. CD4+CD25+CD45RBLow T cells expressed much higher levels of the forkhead family transcription factor, IL-10, and TGFβ1 than CD4+CD25+CD45RBHigh T cells, and these cells can completely suppress the proliferation of the mTg-primed splenocytes in lower concentrations than the unfractionated CD4+CD25+ T cells. Furthermore, transfer of these cells into CBA/J mice prior to mTg-primed splenocyte injection could markedly reduce the frequency and severity of EAT development. CD4+CD25+CD45RBLow T cells were more effective at suppressing histological thyroiditis than unfractionated cells. These results indicated that TRAIL can increase the number of mTg-specific CD4+CD25+CD45RBLow T cells, inhibiting autoimmune responses and preventing the progression of EAT. These findings reveal a novel mechanism by which TRAIL could inhibit autoimmune disease.Keywords
This publication has 49 references indexed in Scilit:
- Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humansNature Reviews Immunology, 2007
- CCR4-dependent regulatory T cell function in inflammatory bowel diseaseThe Journal of Experimental Medicine, 2007
- FOXP3 modifies the phenotypic and functional properties of regulatory T cellsNature Reviews Immunology, 2007
- Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Therapeutic effect of urocortin on collagen‐induced arthritis by down‐regulation of inflammatory and Th1 responses and induction of regulatory T cellsArthritis & Rheumatism, 2007
- Depletion of CD4+CD25+ regulatory T cells exacerbates sodium iodide-induced experimental autoimmune thyroiditis in human leucocyte antigen DR3 (DRB1*0301) transgenic class II-knock-out non-obese diabetic miceClinical and Experimental Immunology, 2007
- Tolerance to autoimmune thyroiditis: CD4+CD25+ regulatory T cells influence susceptibility but do not supersede MHC class II restrictionFrontiers in Bioscience-Landmark, 2006
- Increased CD4+ CD25+ T Regulatory Cell Activity in Trauma Patients Depresses Protective Th1 ImmunityTransactions of the ... Meeting of the American Surgical Association, 2006
- Targeting CD45RB alters T cell migration and delays viral clearanceInternational Immunology, 2005
- Inhibition of Thl responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cellsImmunity, 1994